PreVitaCOV is one of the first drug therapy studies on post-COVID-19-syndrome in Germany. This randomized placebo-controlled pilot study investigates the feasiblity and efficacy of prednisolone and vitamin B1/B6/VitB12 alone or in combination. Study participants will be recruited in general practices and subsequently enrolled and treated in the study centres at the participating trial sites (Würzburg, Tübingen and Kiel).
The pilot study PreVitaCOV will initially investigate feasibility; if successful, it will be transferred to a confirmatory study in which the efficacy and safety of the respective treatment strategies will be investigated in comparison to placebo in an appropriately large study population.
This study, funded by the German Federal Ministry of Education and Research, is being conducted in cooperation with the Institutes for General Medicine of the University Hospitals in Tübingen and Kiel, as well as the Institute of Clinical Pharmacology at the Brandenburg Medical School, the Center for Clinical Studies at the University Hospital in Würzburg, and the Charité Pharmacy.
The project, initially funded for two years, started in February 2022 and enrolment of patients has just begun.
Furthermore, we are looking for general practioners to support the patient recruitment. If you also see patients with post-COVID-19-syndrome in your practice and would like to refer them to our study, please contact us for the Würzburg area at firstname.lastname@example.org.
- University of Tübingen
- University Medical Center Schleswig-Holstein
- Brandenburg Medical School
- Center of Clinical Research at the University Hospital Würzburg